Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: BAX circRNAs in a myelodysplastic syndrome cell line

PROVIDER: PRJNA909063 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22542231_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 1 of 1

Similar Datasets

Project description:BCL2L12 circRNAs in a myelodysplastic syndrome cell line

| PRJNA909061 | ENA

Project description:BAX circRNAs in a B-cell chronic lymphocytic leukemia cell line

| PRJNA909056 | ENA

Project description:BAX circRNAs in acute myeloid leukemia cell lines

| PRJNA909069 | ENA

Project description:BAX circRNAs in a normal breast and eleven breast cancer cell lines

| PRJNA909085 | ENA

Project description:Single cell DNA sequencing of myelodysplastic syndrome

| PRJNA831862 | ENA

Analysis of chromatin accessibility relative to epigenetic features of azacitidine response in high-risk myelodysplastic syndrome

Project description:Azacitidine is used to treat patients with myelodysplastic syndrome, which alters epigenetic regulatory program that changes global gene expression by inhibiting DNA methylation. However, epigenomic factors affecting azacitidine response have not been studied in the context of chromatin. The efficacy of the hypomethylating agent differs by patient, leaving approximately 40% of patients fail to respond. Here, we demonstrate that chromatin accessibility features in patient-derived bone marrow cells can distinguish azacitidine responders from non-responders before treatment. Profiling chromatin accessibility from 23 high-risk myelodysplastic syndrome patients discovered that treatment response is strongly associated with distinct hematopoietic cell states. While non-responders showed enrichment of myeloid progenitor signatures, responders were characterized by elevated T cell populations. Notably, CD8+ T cells from non-responders exhibited selective loss of chromatin accessibility at TBX/EOMES binding sites, revealing a previously unrecognized link between T cell differentiation state and azacitidine response. These findings suggest the importance of immune cell differentiation and their activity in hypomethylating agent response for myelodysplastic syndromes, providing insights for patient stratification and treatment optimization based on the chromatin accessibility in high-risk myelodysplastic syndrome patients.

2025-07-10 | GSE291718 | GEO

Project description:Myelodysplastic syndrome variant detection

| PRJNA631513 | ENA

Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia.

Project description:We used Illumina NGS for high-throughput profiling of the DNA methylome (ERRBS) for myelodysplastic syndrome (MDS) iPSC cell lines. We performed DNA methylation analysis of the low-risk MDS1.12 cells (iPSC cell line) treated with 5-AzaC- and show that profound hypomethylation changes can be detected following treatment with 5-AzaC and support the use of our stage-specific induced pluripotent stem cells system to study mechanisms of drug action.

2017-02-17 | GSE93507 | GEO

High expression of circZBTB46 predicts poor prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia

Project description:This study aimed to find the functional circular RNA and further analyze its biological and clinical significance in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients.The circRNAs profiles were analyzed using the Arraystar human circRNA microarray with bone marrow samples from 5 MDS patients, 5 AML patients and 4 controls. Real-time quantitative polymerase chain reaction was carried on circZBTB46 in bone marrow samples from 124 MDS patients, 116 AML patients and 37 controls, and subsequently associated with clinicopathological characteristics and survival of MDS and AML patients.Furthermore, functional studies were conducted by silencing and rescuing/increasing circZBTB46 expression in SKM-1, THP-1 and K562 cell lines. Our results suggested the essential role of circZBTB46 in the progression of MDS and AML, and might be a poor indicator of hematological malignancies.

2020-12-17 | GSE163386 | GEO

Expression data of ribosomal proteins from sorted hematopoietic stems cells from patients with low risk MDS.

Project description:A role for reduced ribosomal protein gene dosage in both DBA and 5q- MDS suggests that other forms of MDS might also involve altered expression of ribosomal protein genes. We used microarrays to interrogate the expression of ribosomal proteins from purified hematopoietic stems cells from patients with low risk myelodysplastic syndrome and age-matched healthy controls. Hematopoietic stem cells were sorted from 8 patients with low risk myelodysplastic syndrome and 11 age-matched healthy controls, and total RNA was hybridized to Affymetrix microarrays.

2011-08-13 | E-GEOD-30201 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data